

## CURRICULUM VITAE

### **PERSONAL DETAILS:**

Full Name: Professor Brian Gregory PRIESTLY

Current appointment: (Since Dec 2003) Director, Australian Centre for Human Health Risk Assessment (ACHHRA)  
Professorial Fellow, Department of Epidemiology & Preventive Medicine  
School of Applied Clinical & Public Health Sciences, Monash University  
The Alfred Hospital, Prahran Vic 3004  
Work phone: 03 9903 0531 Work fax: 03 9903 0556  
Mobile: 0413 607 285  
Email: [brian.priestly@med.monash.edu.au](mailto:brian.priestly@med.monash.edu.au)

### **DEGREES AND DIPLOMAS:**

1963 B. Pharm – Sydney University.

1965 M.Pharm – Sydney University

1968 PhD – Sydney University

### **PAST APPOINTMENTS:**

1964-67 Teaching Fellow (Demonstrator) Pharmacy School, University of Sydney

1968 Research Associate, Department of Pharmacology, University of Iowa

1968-70 Canadian MRC Postdoctoral Fellow, Department of Pharmacology, University of Montreal

1970-80 Lecturer/Sen. Lecturer, Dept. of Human Physiology and Pharmacology, University of Adelaide

1975-76 Professeur invite, Department of Pharmacology, University of Montreal,

1980 -92 Senior Lecturer, Dept. of Clinical and Experimental Pharmacology, University of Adelaide (Deputy Head)

1992-95 Senior Principal Research Scientist, (SPRS), & Scientific Director, Chemicals Safety Unit, Commonwealth Dept of Community Services & Health

1995-96 Scientific Director, (SPRS) Environmental Health & Safety Unit, Commonwealth Dept. Human Services & Health

1996-2001 Scientific Director, (SPRS) Chemicals & Non-Prescription Medicines Branch, Therapeutic Goods Administration, Commonwealth Dept. Health & Aged Care

2001-03 Director (SPRS), Laboratories Branch, Therapeutic Goods Administration (TGA), Commonwealth Dept. of Health & Ageing

## **CAREER RESEARCH AND OTHER PROFESSIONAL INTERESTS:**

- Pre-1992 Mechanisms of chemically-induced cytotoxicity, with particular interest in hepatotoxic chemicals and the use of isolated hepatocytes/cell cultures to determine drug metabolism and toxicological mechanisms. Metabolic activation/inactivation and genotoxicity of carcinogenic chemicals with applications to biological monitoring of occupational chemical exposure. Oxidant stress and the role it may play in mediating or modifying chemically-induced toxicity.
- 1992-2001: Risk assessment and regulatory control of hazardous chemicals, including: management of toxicological and public health assessments for agricultural, veterinary and industrial chemicals for the relevant Australian regulatory authorities; responsibility for policy development for national and international chemicals regulatory activities; advice on regulation of OTC and complementary medicines; community liaison on hazardous chemicals issues
- 2001- 03 As Director of the TGA Laboratories, duties included overall management of the delivery of scientific and laboratory testing services in support of the regulation of therapeutic goods in Australia (medicines, medical devices); budget management responsibilities \$14.2m; policy formulation on therapeutic goods regulation; liaison with stakeholders (industry, governments and the community) on laboratory testing of therapeutic goods.
- 2004- As Director of the Australian Centre for Human Health Risk Assessment (ACHHRA), to develop ACHHRA as a leading Australian centre of excellence in health risk assessment; to co-ordinate workforce development and training programs in health risk assessment; to maintain appropriate linkages with government public & environmental health and regulatory programs; to promote Australian contributions to national and international chemicals risk assessment and risk management programs.

## **RECENT AND CURRENT MEMBERSHIP OF EXTRAMURAL COMMITTEES (2003-05):**

National Drugs & Poisons Schedule Committee (NDPSC)  
NDPSC Working Party on Trans-Tasman Harmonisation of Scheduling of Drugs & Poisons  
NHMRC Special Expert Committee on Transmissible Spongiform Encephalopathies (Observer)  
National Research Centre for Environmental Toxicology - Research Advisory Committee  
Official Medicines Control Laboratories network  
International Laboratory Forum on Counterfeit Medicines  
Inter-Departmental Committee on BSE & TSE  
TGA-Industry Consultative Committee  
NHMRC Working Group on Toxicity & Risk Assessment

## **PAST MEMBERSHIP OF EXTRAMURAL COMMITTEES:**

- 1. Editorial Boards:**  
Toxicology (1977-78)
- 2. National Health and Medical Research Council:**  
Committee on Toxicity (1985-92)  
Drugs and Poisons Schedule Committee (1980-85)  
Food Science & Technology Committee (1982-91)  
Consumer Products Safety Committee (1979-82)  
WP on Heavy Metal Contamination of seafoods (1973)  
WP on the use and safety of 2,4,5-T (1978-80)  
WP on Fluoridation (1979 & 1989-90)  
WP on urea-formaldehyde foam insulation (1982)  
WP on dichlorvos (1984-86)  
WP on plasticisers (1987)  
WP on cancer risk assessment (1995-96)
- 3. Commonwealth Department of Health:**  
Australian Drug Evaluation Committee (Assoc member) (1992)  
Advisory Committee on Pesticides & Health (Chair; 1996-2001)  
Chemicals Clearing House (Inter-Departmental Committee) (Chair 1996-2001)  
IDC on Health Monitoring program (Chair; 2000-01)
- 4. Other Government Committees & Working Parties:**  
Forest Herbicides Management Working Group; 1995-1999  
National Coordination Team for a National Profile on Chemicals Management Infrastructure in Australia, 1997-98  
National Pollutants Inventory Technical Advisory Panel, 1997-98

Working Party on hazardous chemicals, Trans-Tasman Mutual Recognition Arrangements, 1999-2002  
Workshop participant for the development of a Draft framework for Environmental Health Risk Assessment, 1999-2000  
Working Party on the Health Impacts of Pesticide Odours 2000-01  
Working Party to develop a risk management framework for recycled water (2004-)

5. **SA Government:**

Food and Drug Advisory Committee 1979 - 1992.  
Controlled Substances Advisory Council 1985 - 1992.  
Animal Welfare Advisory Committee 1988-1992  
Scientific Data Review Working Party (Chairman) 1980-1985  
Working Party to review the Level of Concern for Lead 1986  
Ministerial Working Party on Toxicity of Aldrin, 1987  
Ministerial Scientific and Advisory Committee on Aldrin Contamination, Streaky Bay Area School 1987-1989  
CSAC Working Party on Termiticides 1988-1989

6. **University & Hospital Committees:**

Adelaide University Animal Ethics Committee (1990-92; medical sub-group 1980-92; agricultural & natural sciences sub-group 1990-92)  
Adelaide University Biosafety Committee (1985-92)  
Faculty of Science (Dept representative) 1971-92)  
Anti-Cancer Foundation of the Universities of South Australia Executive Board (1980-91)  
Queen Elizabeth Hospital Ethics of Research Committee (1983-89)

7. **International:**

International Agency for Research on Cancer (IARC) (Member, Monograph Working Party on Pesticides, 1990)  
Joint FAO/WHO Expert Committee on Food Additives (JECFA) (Temporary Advisor 39th. JECFA Meeting, 1992. Member, Expert Panel on Food Safety 1993-  
Joint FAO/WHO Meeting on Pesticide Residues (JMPPR) (Member 1997-2001)  
International Programme on Chemical Safety (IPCS)  
INTOX-VI 1993; Harmonisation of Risk Assessment 1993; Workshop/Planning meeting on Biomarkers in Risk Assessment 1993; IPCS/OECD Consultation on Priority Chemicals & Related Issues 1995; Internationalization of National & Regional Criteria Documents (Chair) 1995; Consultation to Review the Terms of Reference of the Programme Advisory Committee, 1995; Member, Programme Advisory Committee (PAC) 1996-2001; PAC Standing Committee 1998-2001 ; Cancer Risk Assessment Workshop 1998; Meeting on Peer Review Processes for Risk Assessment 1998  
Codex Committee on Veterinary Drug Residues (Member, Australian delegation, 1992)  
Intergovernmental Forum on Chemical Safety (IFCS)  
2nd Intersessional Meeting, Canberra 1996, member of Australian delegation  
2nd Session IFCS, Ottawa 1997, Deputy Head of Australian delegation  
ILSI/HESI Agricultural Chemical Safety Steering Group

11. **Miscellaneous**

International Advisory Board, Xth International Congress of Pharmacology, Member 1986-1987.  
International Union of Toxicology (IUTOX), Director 1992-1995  
Australasian Society of Clinical and Experimental Pharmacologists & Toxicologists (ASCEPT).  
Member 1971-2001; Served on Council, 1982-1985; 1992; 1999-2000;  
Toxicology Committee, Convenor 1982-1983; Secretary 1990-94;  
Member of the Executive Committee of the International Congress of Toxicology IX Organising Committee, and Chair of the Programme Committee, 1995-2000.

***MEMBERSHIP OF SOCIETIES:***

1. Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (1971-2001)

***GRADUATE STUDENT SUPERVISION BY BRIAN PRIESTLY 1970-92***

11 PhD; 2 M.Env.studies; 17 BSc (Hons)

## PUBLICATIONS:

- 1 PRIESTLY BG & O'REILLY WJ (1966). Protein binding and the excretion of some azo dyes in rat bile. *J. Pharm. Pharmacol.* **18**, 41-45.
- 2 PRIESTLY BG & PLAA GL. (1969). Effects of benziodarone on the metabolism and biliary excretion of sulfobromophthalein and related dyes. *Proc. Soc. Exp. Biol. Med.*, **132**, 881-885.
- 3 PRIESTLY BG & PLAA GL. (1970). Sulfobromophthalein metabolism and excretion in rats with iodomethane-induced depletion of hepatic glutathione. *J. Pharmacol. Exp. Ther.*, **174**, 221-231.
- 4 PRIESTLY BG & PLAA GL. (1970). Reduced bile flow after sulfobromophthalein administration in the rat. *Proc. Soc. Exp. Biol. Med.*, **135**, 373-376.
- 5 PRIESTLY BG & PLAA GL. (1970). Temporal aspects of carbon tetrachloride-induced alteration of sulfobromophthalein excretion and metabolism. *Toxicol. Appl. Pharmacol.*, **17**, 786-794.
- 6 PRIESTLY BG, COTE MG & PLAA GL. (1971). Biochemical and morphological parameters of tauroolithocholate-induced cholestasis. *Canad. J. Physiol. Pharmacol.*, **49**, 1078-1091.
- 7 O'REILLY WJ, COATES PE, MCMAHON KA, TING E & PRIESTLY BG. (1972). Pharmacokinetic models for the biliary excretion of amaranth in the rat. *Life Sci.*, **11**, 197-208.
- 8 WILLIAMS DE & PRIESTLY BG (1973). Evaluation of prophylactic efficacy of silymarin in CCl<sub>4</sub>-induced hepatotoxicity. *Res. Comm. Chem. Path. Pharmacol.*, **6**, 185-194.
- 9 DREW R & PRIESTLY BG. (1976). Microsomal drug metabolism during  $\alpha$ -naphthylisothiocyanate-induced cholestasis. *Toxicol. Appl. Pharmacol.* **35**, 491-499.
- 10 DREW R & PRIESTLY BG. (1976). Hexobarbital sleeping time and drug metabolism in rats with ligated bile ducts - a lack of correlation. *Biochem. Pharmacol.*, **25**, 1659-1663.
- 11 HANASONO GK, DE REPENTIGNY L, PRIESTLY BG & PLAA GL. (1976). The effects of oral diazepam pretreatment on the biliary excretion of sulfobromophthalein in rats. *Canad. J. Physiol. Pharmacol.*, **54**, 603-612.
- 12 STACEY NH & PRIESTLY BG (1976). The bicarbonate ion concentration of Krebs-Henseleit solution. *Aust. J. Exp. Biol. Med. Sci.*, **54**, 103-105.
- 13 PRIESTLY BG & PLAA GL. (1976). Hepatic function after acute or subchronic nicotine administration in untreated mice and mice treated with hepatotoxic chemicals. *Arch. Int. Pharmacodyn. Ther.*, **223**, 132-141.
- 14 PLAA GL & PRIESTLY BG. (1977). Intrahepatic cholestasis induced by drugs and chemicals. *Pharmacol. Rev.*, **28**, 207-273.
- 15 DREW R, PRIESTLY BG & O'REILLY WJ. (1977). Hexobarbital pharmacokinetics in rats after ligation of the common bile duct. *J. Pharmacol. Exp. Ther.*, **201**, 534-540.
- 16 HARMAN AW, PENHALL RK, PRIESTLY BG, FREWIN DB, PHILLIPS PJ & CLARKSON A. (1977). Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy. *Aust. N.Z. J. Med.*, **7**, 385-390.
- 17 HARMAN AW, PRIESTLY BG & FREWIN DB. (1977). A comparative study of antipyrine pharmacokinetics in saliva and plasma using a colourimetric method of antipyrine analysis. *Clin. Exp. Physiol. Pharmacol.*, **4**, 593-596.
- 18 STACEY NH, PRIESTLY BG, HALL RC. (1978). Toxicity of halogenated volatile anesthetics in isolated rat hepatocytes. *Anesthesiology*, **48**, 17-22.
- 19 STACEY NH, COOK R & PRIESTLY BG. (1978). Comparative stability of alanine aminotransferase in rat plasma and hepatocyte suspensions. *Aust. J. Exp. Biol. Med. Sci.*, **56**, 379-381.
- 20 HARMAN AW, RUSSELL WJ, FREWIN DB & PRIESTLY BG. (1978). Altered drug metabolism in anaesthetists exposed to volatile anaesthetic agents. *Anaesth. Inten. Care*, **6**, 210-214.
- 21 LAVIGNE J, PRIESTLY BG & PLAA GL. (1978). Effects of a cholestatic agent on isolated rat hepatocyte function. *Toxicol. Appl. Pharmacol.*, **45**, 263.

- 22 DREW R & PRIESTLY BG. (1978). Failure of hypoactive hypertrophic smooth endoplasmic reticulum to produce cholestasis in rats. *Toxicol. Appl. Pharmacol.*, **45**, 191-199.
- 23 STACEY NH & PRIESTLY BG. (1978). Lipid peroxidation in isolated rat hepatocytes: relationship to toxicity of CCl<sub>4</sub>, ADP/Fe<sup>3+</sup>, and diethyl maleate. *Toxicol. Appl. Pharmacol.*, **45**, 41-48.
- 24 STACEY NH & PRIESTLY BG. (1978). Dose-dependent toxicity of CCl<sub>4</sub> in isolated rat hepatocytes and the effects of hepatoprotective treatments. *Toxicol. Appl. Pharmacol.*, **45**, 29-39.
- 25 HARMAN AW, FREWIN DB, PRIESTLY BG & ALEXANDER CBJ. (1979). Impairment of hepatic metabolism in alcoholics. *Brit. J. Clin. Pharmacol.*, **7**, 45-48.
- 26 DREW R & PRIESTLY BG. (1979). Choleric and cholestatic effects of infused bile salts in the rat. *Experientia*, **35**, 809-810.
- 27 DREW R & PRIESTLY BG. (1979). Effect of chlorpromazine and erythromycin on bile salt-induced cholestasis in the rat. *Pharmacology*, **18**, 202-209.
- 28 PENHALL RK, HARMAN AW, FREWIN DB & PRIESTLY BG. (1979). A comparison of the efficacy of atenolol give once a day with either propranolol or pindolol in the management of hypertension. *Current Therapeutics*, **20** Suppl, 4-10.
- 29 HARMAN AW, FREWIN DB & PRIESTLY BG. (1980). Comparative enzyme-inducing effects of chlorpromazine and fluphenazine therapies in psychotic patients. *Psychopharmacol.*, **69**, 35-37.
- 30 HARMAN AW, FREWIN DB & PRIESTLY BG. (1981). Induction of microsomal drug metabolism in man and in the rat by exposure to petroleum. *Brit. J. Indust. Med.*, **38**, 91-97.
- 31 PRIESTLY BG. (1984). Interpretation of drug mutagenicity tests (commentary). *Med. J. Aust.*, **141**, 166-167.
- 32 PRIESTLY BG. (1984). Handling cytostatic drugs. *Q.E.H. Newsletter*, p.3, September.
- 33 STOCK JK & PRIESTLY BG. (1986). Urinary thioether output as an index of occupational chemical exposure in petroleum retailers. *Brit. J. Indust. Med.*, **43**, 718-720.
- 34 BRUSCHI S & PRIESTLY BG. (1989). Effects of β-naphthoflavone induction on microsomal oxygenase activity and acetaminophen-mediated cytotoxicity in differentiated human hepatoma cell line (HH<sub>1</sub>). *In Vitro Toxicol.* **2**, 91-99.
- 35 BRUSCHI S & PRIESTLY BG. (1990). Implications of alteration in intracellular calcium ion homeostasis in the advent of paracetamol-induced cytotoxicity in primary mouse hepatocyte monolayer cultures. *Toxicol In Vitro*, **4**, 743-749, 1990.
- 36 SIMULA AP & PRIESTLY BG. (1991). The influence of vegetable oil vehicles on bone marrow proliferation in the mouse micronucleus test. *Mutation Res.* **261**, 83-84
- 37 SIMULA AP & PRIESTLY BG. (1992). Species differences in the genotoxicity of cyclophosphamide and styrene in three in vivo assays. *Mutation Res.* **271**, 49-58
- 38 EDWARDS JW & PRIESTLY BG. (1992). Biological and biological-effect monitoring of workers exposed to 4,4'-methylene bis (2-chloroaniline) (MOCA). *Human & Expt. Toxicol.* **11**, 229-236
- 39 NICHOLLS-GRZEMSKI FA, CALDER IC & PRIESTLY BG. (1992). Peroxisome proliferators protect against paracetamol hepatotoxicity in mice. *Biochem. Pharmacol.* **43**, 1395-1396
- 40 EDWARDS JW & PRIESTLY BG (1993) Sister chromatid exchange in lymphocytes of petroleum retailers. *Brit. J. Indust. Med.* **50**, 149-154.
- 41 EDWARDS JW & PRIESTLY BG (1994) Effect of occupational exposure to aldrin on urinary D-glucaric acid, plasma dieldrin and lymphocyte sister chromatid exchange. *Int. Arch. Occup. Environ. Health.* **66**, 229-234.
- 42 NICHOLLS-GRZEMKI FA, BURCHAM PC, CALDER IC & PRIESTLY BG (1996). Pretreatment with peroxisome-proliferators protects mice against some, but not all, hepatotoxins. *Ann. NY Acad. Sci.* **804**, 742-744
- 43 DI MARCO PN, DREW R, PRIESTLY BG & WRIGHT PFA (1996). Health based risk assessment of contaminated land: Focus on carcinogens. Report of the ASCEPT Workshop. In *The health risk assessment and management of contaminated sites*, Proceedings of the Third

National Workshop on the health risk assessment and management of contaminated sites. Edited by Langley A, Markey B & Hill H. South Australian Health Commission, Contaminated Sites Monograph series 5: pp 275-278.

- 44 DI MARCO PD, PRIESTLY B.G. & BUCKETT KJ (1998). Carcinogen risk assessment. Can we harmonise? *Toxicology Letters* **102-103**; 241-246.
- 45 DI MARCO PD, ANDERSSON R, BADENOCH-JONES J, FITZGERALD J, LANGLEY J, MARKEY B, PRIESTLY B, PORTIER CJ, ROBERTON D & CALLAN P (1999). Toxicity assessment for carcinogenic soil contaminants. National Health & Medical Research Council, Canberra <http://www.nhmrc.gov.au/publications/pdf/eh21.pdf>
- 46 NICHOLLS-GRZEMSKI FA, CALDER IC, PRIESTLY BG & BURCHAM PC (2000). Clofibrate-induced in vitro hepatoprotection against acetaminophen is not due to altered glutathione homeostasis. *Toxicological Sciences* **56**, 220-228
- 47 NICHOLLS-GRZEMSKI FA, BELLING GB, PRIESTLY BG, CALDER IC & BURCHAM PC (2000) Clofibrate treatment in mice confers resistance against lipid peroxidation. *J. Biochem. Mol. Toxicol.* **14**, 335-345
- 48 PRIESTLY BG, NOLLER B, MOORE M & NG J (2004) Human health risk assessment on the potable water contamination incident at Ranger Mine March 2004. Supervising Scientist Report 184, Supervising Scientist, Australian Government Department of the Environment & Heritage, pp 106-172. <http://www.deh.gov.au/ssd/publications/ssr/184.html>